SJP-002C
Upper Respiratory Infections, including COVID-19 (Mild to Moderate)
Phase 2Active
Key Facts
Indication
Upper Respiratory Infections, including COVID-19 (Mild to Moderate)
Phase
Phase 2
Status
Active
Company
About Sen-Jam Pharmaceutical
Sen-Jam Pharmaceutical is an early-stage biotech pioneering a novel approach to immuno-regulation with its PAIR platform, which combines two repurposed molecules to modulate inflammation upstream. The company has a broad pipeline spanning from preclinical to Phase 2, targeting multi-trillion-dollar health burdens including obesity/MASH, opioid use disorder, respiratory infections, and critical care inflammation. By aiming to shift treatment paradigms from reactive symptom management to proactive immune modulation, Sen-Jam seeks to extend healthspan and reduce the global economic burden of chronic disease.
View full company profile